CRNO B — Cereno Scientific AB Share News
0.000.00%
Last trade - 00:00- SEK1.50bn
- SEK1.60bn
Brief: Cereno Scientific Strengthens Patent Protection For Cs1 In Canada
Sweden's Cereno Scientific Q1 net loss widens amid clinical development
Brief: Cereno Scientific Q1 Loss After Financial Items SEK 28.6 Mln
Brief: Cereno Enters Collaboration With PHA Europe & Global
Brief: Cereno Reports Favorable Safety, Tolerability Of CS1 Treatment In PAH
Brief: Cereno Scientific Receives Approval To Initiate FDA-Aligned Phase I Pharmacokinetic Study Of Cs014 Supporting Phase Ii Development In Ph-Ild
Brief: Cereno Scientific Q4 Loss SEK 44.7 Mln
Sweden's Cereno Scientific reports bigger annual loss
Brief: Cereno Scientific Receives About SEK 5 Mln From Warrants
Brief: Cereno Scientific Receives FDA Clearance To Initiate Global Phase IIb Trial Of CS1 In Pulmonary Arterial Hypertension
Corrected: BRIEF-Cereno Scientific AB Announces Financing Arrangement Up To SEK 665 Million With Major Shareholders And New Investors
Brief: Cereno Scientific AB Announces Financing Arrangement Up To Sek 650 Million With Major Shareholders And New Investors
Brief: Cereno Scientific Secures SEK 100 Mln In Directed Share Issue And Loan Financing Of SEK 350 Mln
Brief: Cereno Scientific Q3 Adjusted EPS SEK -0.07
Brief: Cereno Scientific Receives SEK 4 Mln Through Exercise Of Warrants
Brief: Cereno Scientific Submits Trial Protocol To U.S. FDA
Brief: Cereno Scientific Q2 Loss After Financial Items At SEK 26.6 Million
Brief: Cereno Scientific Granted FDA Fast Track For CS1 In PAH Treatment
Brief: Cereno Announces Positive Results From Phase I Trial Of Cs014